Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call hosted by CEO Joe Kiani and CFO Micah Young will occur at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. This event is crucial for investors as Masimo's innovative medical technologies aim to improve patient outcomes and reduce care costs. Interested participants can register for the call to receive necessary details. More information about Masimo and its products is available on its website.

Masimo (NASDAQ: MASI) has issued a statement responding to a lawsuit filed by Politan Capital Management in Delaware. The company claims the lawsuit follows Politan's failed attempts to gain a board seat for its founder, Quentin Koffey, who lacks relevant industry experience. Masimo's board emphasizes the adoption of bylaw amendments to enhance transparency for shareholders and reject Politan's demands as self-serving. The legal team includes prestigious law firms like Quinn Emanuel Urquhart & Sullivan LLP.

Politan Capital Management, holding 8.8% of Masimo (NASDAQ: MASI), has filed a lawsuit against the company following recent bylaws amendments. These amendments, implemented on September 9, 2022, effectively hinder stockholders' rights to nominate directors, requiring sensitive information that is often confidential. The lawsuit seeks to declare the amendments unenforceable and challenges the directors' fiduciary duties. Quentin Koffey of Politan stated that Masimo's defensive measures, including a poison pill and a staggered board, leave them no option but to pursue legal action to preserve stockholder rights.

Masimo has appointed Blair Tripodi as Chief Operating Officer of its Consumer division, effective immediately. Tripodi, previously the Chief Commercial Officer at Sound United, will oversee sales, product, marketing, and commercial operations for Masimo Consumer. Founder and CEO Joe Kiani expressed confidence that Tripodi's experience in marketing and sales will drive growth in consumer health products. This leadership change aims to enhance innovation in audio products and healthcare technologies, reinforcing Masimo's commitment to improving lives through advanced solutions.

Masimo (NASDAQ: MASI) has announced the full market release of its innovative Masimo W1™ health watch, which offers continuous monitoring of vital signs such as oxygen saturation, pulse rate, and hydration index. Designed for consumer use, the watch utilizes advanced technology known for its accuracy in challenging conditions. Additionally, it pairs with the Masimo Health™ app for insightful health data tracking. The launch includes the Personal SafetyNet™ subscription service for enhanced health monitoring over time.

Masimo (Nasdaq: MASI) reported strong Q2 2022 results with consolidated revenue of $565 million, an increase of 85.3% from $305.1 million in Q2 2021. Healthcare revenue grew by 17% to $357 million, while non-healthcare revenue reached $208 million. GAAP net income was $18.1 million ($0.33 per diluted share), with non-GAAP net income of $74.8 million ($1.35 per diluted share). The company repurchased 3 million shares for $401 million and provided optimistic guidance for Q3 and FY 2022.

Masimo (NASDAQ: MASI) will release its second quarter 2022 financial results after market close on August 9, 2022. The results will be reviewed in a conference call at 1:30 p.m. PT (4:30 p.m. ET) hosted by CEO Joe Kiani and CFO Micah Young. Masimo is recognized for its innovative medical monitoring technologies, including the SET pulse oximetry system, which has shown superior performance in numerous studies. The company's advancements aim to enhance patient outcomes while minimizing healthcare costs.

Masimo (NASDAQ: MASI) announced findings from a randomized trial published in the Journal of Clinical Anesthesia, showing that EEG-guided anesthesia using Masimo's SedLine technology reduces sevoflurane dosage in young children undergoing minor surgery. The trial involved 195 children, revealing a significant decrease in average sevoflurane concentrations during induction (4.80% vs. 5.67%) and maintenance (2.23% vs. 2.38%) phases. Additionally, burst suppression incidents were lower in the EEG group (3.1% vs. 10.9%). These results suggest potential for enhanced anesthesia management in pediatric populations.

Masimo (NASDAQ: MASI) released findings from a retrospective study in Telemedicine and e-Health analyzing the efficacy of its SafetyNet remote patient monitoring system for COVID-19 patients. Conducted by the University of Colorado, the study suggested that Masimo SafetyNet is associated with a decrease in hospital length of stay (LOS) without increasing readmission rates. Out of 1979 patients analyzed, those discharged with SafetyNet had a notable reduction in LOS of 36% when not on home oxygen. The research highlights the potential of home telemonitoring to ease hospital capacity issues during surges in COVID-19 cases.